BioSpace News Archive

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021 financial results on Thursday, April 22, 2021, after market close.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics in healthcare.

– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments

BetterLife Pharma Inc., an emerging biotechnology company developing second generation psychedelics for neuro-psychiatric disorders, announced that Dr. Thomas Laughren will join BetterLife as a Regulatory Advisor.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced the top-line results from the SAVIOR-1 study, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stimulation using gammaCore Sapphire in patients admitted to the hospital for treatment of COVID-19 between April 2020 and February 2021.

Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, and Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, today announced a research collaboration and licensing agreement for the development of an anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for gynecologic cancer therapy.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday, May 6, 2021, after the close of the market.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new preclinical research highlighting novel mechanisms by which SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) enters host cells and identifying how auxiliary receptors may impact the clinical efficacy of monoclonal antibodies (mAbs).

BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced publication of new research entitled “Plasma gelsolin modulates the production and fate of IL-1β-containing microparticles following high-pressure exposure and decompression” in the Journal of Applied Physiology.

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021.